Argentinean crackdown on pharma imports causes problems for industry
This article was originally published in SRA
Protectionist measures aimed at improving Argentina's trade balance are causing problems for both local and multinational pharmaceutical companies operating in the country. Nevertheless, talks between the government and industry are ongoing and the ministry for industry has hinted that import restrictions may be eased in certain circumstances.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.